Kyverna Therapeutics, Inc.
KYTX
$8.17
$0.091.11%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -152.64M | -156.40M | -161.31M | -160.99M | -158.70M |
| Total Depreciation and Amortization | 1.57M | 1.65M | 1.80M | 1.99M | 2.14M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 10.98M | 8.64M | 6.87M | 4.53M | 3.82M |
| Change in Net Operating Assets | -18.67M | -4.29M | -1.08M | -2.78M | 11.33M |
| Cash from Operations | -158.75M | -150.39M | -153.71M | -157.25M | -141.41M |
| Capital Expenditure | -294.00K | -5.00K | -5.00K | -538.00K | -638.00K |
| Sale of Property, Plant, and Equipment | 70.00K | 70.00K | 70.00K | 70.00K | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -8.58M | -15.83M | 39.95M | 86.99M | 65.28M |
| Cash from Investing | -8.80M | -15.76M | 40.02M | 86.52M | 64.64M |
| Total Debt Issued | 24.70M | 24.70M | 24.70M | -- | -- |
| Total Debt Repaid | -386.00K | -553.00K | -808.00K | -970.00K | -1.09M |
| Issuance of Common Stock | 122.28M | 118.14M | 117.90M | 1.69M | 125.00K |
| Repurchase of Common Stock | -470.00K | -333.00K | -144.00K | -94.00K | -51.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -201.00K | -468.00K | -475.00K | -412.00K | -412.00K |
| Cash from Financing | 145.92M | 141.48M | 141.17M | 210.00K | -1.43M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -21.63M | -24.68M | 27.47M | -70.51M | -78.20M |